Concept
Other concurrent therapies in evaluating outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
All patients recieved standard treatment during the study.
-
Medications:
- antiviral drugs lopinavir 400mg and ritonavir 100 mg 2x/day or remdesivir 100 mg/day
- antibiotic prophylaxis (azithromycin, ceftriaxone or piperacillin/tazobactam)
- hydroxychloroquine 400 mg/day
- dexamethasone 20 mg/ day
-
Ventilation (non-invasive or tracheal intubation as needed)
0
1
Updated 2020-06-15
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Brescia COVID-19 Respiratory Severity Scale (BCRSS)
Tocilizumab (TCZ) infusion dosage for study of outcomes among 100 severe COVID-19 patients in Brescia, Italy
Other concurrent therapies in evaluating outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion
Population selection to track outcomes among 100 severe COVID-19 patients in Brescia, Italy after Tocilizumab (TCZ) infusion